Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 8Gastrointestinal 3Myeloid 1Head & Neck 1Genitourinary 1CNS 1

Conditions

Glioma 2Brain Neoplasms 2Thyroid Neoplasms 1Lung Neoplasms 1Histiocytosis 1Gliosarcoma 1Glioblastoma 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Magnetic Resonance Spectroscopy 19Radiosurgery 16Radiotherapy 14Specimen Handling 11Pemetrexed 8Paclitaxel 6Erlotinib Hydrochloride 6Docetaxel 6Carboplatin 6Bevacizumab 5pembrolizumab 4Temozolomide 4Spinal Puncture 4Cisplatin 4osimertinib 3Taxes 3Nivolumab 3Gemcitabine 3Gefitinib 3Filgrastim 3Drug Therapy 3trametinib 2selpercatinib 2sapanisertib 2motexafin gadolinium 2epothilone B 2dabrafenib 2X-Rays 2Vorinostat 2Trastuzumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lung Neoplasms × Panitumumab × CNS × Clear all
NCT05786924 2026-04-21

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Servier

Phase 1/2 Recruiting
554 enrolled
CNSGastrointestinalHead & NeckMyeloidThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Histiocytosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡